PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-32.06%
Negative ROE while Biotechnology median is -8.43%. Seth Klarman would investigate if capital structure or industry issues are at play.
-28.35%
Negative ROA while Biotechnology median is -8.65%. Seth Klarman would consider if assets are underutilized or if it’s a distressed opportunity.
-31.81%
Negative ROCE while Biotechnology median is -9.03%. Seth Klarman would investigate whether a turnaround is viable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.